ProPhase Labs Plans Tender Offer

ProPhase Labs, a natural health medical science company, said late Tuesday it intends to commence a tender offer to purchase up to 4 million shares at a price of $2.30 per share, providing liquidity to the stock. The tender offer, which represents about 24.7% of the total outstanding capital, is expected to be launched on or before Aug. 25, according to a statement. It will remain open for at least 20 business days from initiation.

CEO Ted Karkus has irrevocably committed to tendering 500,000 shares on the same terms and conditions as are offered to all other stockholders.